Per-Anders Abrahamsson (Former)
1 – 125 of 125
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
A non-invasive 25-Gene PLNM-Score urine test for detection of prostate cancer pelvic lymph node metastasis
2024) In Prostate Cancer and Prostatic Diseases(
- Contribution to journal › Article
- 2021
-
Mark
Androgen deprivation therapy and side effects : Are GnRH antagonists safer?
(
- Contribution to journal › Scientific review
-
Mark
Impact of Cernitin™ on induced chronic prostatitis in animal model for understanding management of lower urinary tract symptoms
(
- Contribution to journal › Article
-
Mark
Non-invasive Urine Test for Molecular Classification of Clinical Significance in Newly Diagnosed Prostate Cancer Patients
(
- Contribution to journal › Article
- 2020
-
Mark
Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up
(
- Contribution to journal › Article
-
Mark
Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer
(
- Contribution to journal › Scientific review
- 2019
-
Mark
The effects of Cernitin® on inflammatory parameters and benign prostatic hyperplasia : An in vitro study
(
- Contribution to journal › Article
-
Mark
Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer : The European Association of Urology Position in 2019
(
- Contribution to journal › Article
- 2017
-
Mark
Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy
(
- Contribution to journal › Article
-
Mark
Intermittent androgen deprivation therapy in patients with prostate cancer : Connecting the dots
(
- Contribution to journal › Article
- 2016
-
Mark
Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells
(
- Contribution to journal › Article
- 2015
-
Mark
Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe.
(
- Contribution to journal › Scientific review
-
Mark
Influence of Melatonin on the Proliferative and Apoptotic Responses of the Prostate under Normal and Hyperglycemic Conditions.
(
- Contribution to journal › Article
-
Mark
Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death.
(
- Contribution to journal › Article
- 2014
-
Mark
AKT and AMPK Activation after High-Fat and High-Glucose In Vitro Treatment of Prostate Epithelial Cells.
(
- Contribution to journal › Article
-
Mark
Still a long way to go to achieve multidisciplinarity for the benefit of patients: commentary on the ESMO position paper (Annals Oncology Jan;25(1): 9-15, 2014).
(
- Contribution to journal › Letter
-
Mark
Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?
(
- Contribution to journal › Scientific review
-
Mark
Protein kinase A (PKA) pathway is functionally linked to androgen receptor (AR) in the progression of prostate cancer.
(
- Contribution to journal › Article
-
Mark
EAU Policy on Live Surgery Events.
(
- Contribution to journal › Scientific review
- 2013
-
Mark
Intermittent Androgen-deprivation Therapy in Prostate Cancer: A Critical Review Focused on Phase 3 Trials
(
- Contribution to journal › Article
-
Mark
Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate Cancer.
(
- Contribution to journal › Article
-
Mark
Early Detection of Prostate Cancer: European Association of Urology Recommendation
(
- Contribution to journal › Article
-
Mark
New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists
(
- Contribution to journal › Scientific review
- 2012
-
Mark
The androgen receptor and stem cell pathways in prostate and bladder cancers (Review)
(
- Contribution to journal › Scientific review
-
Mark
Current Vaccination Strategies for Prostate Cancer
(
- Contribution to journal › Scientific review
-
Mark
The Effect of Baseline Testosterone on the Efficacy of Degarelix and Leuprolide: Further Insights From A 12-Month, Comparative, Phase III Study in Prostate Cancer Patients
(
- Contribution to journal › Article
-
Mark
Regional distribution of neuroendocrine cells in the urogenital duct system of the male rat
(
- Contribution to journal › Article
-
Mark
Testosterone in prostate cancer: the Bethesda consensus.
(
- Contribution to journal › Article
-
Mark
Microdialysis in Early Detection of Temporary Pancreatic Ischemia in a Porcine Model.
(
- Contribution to journal › Article
-
Mark
Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.
(
- Contribution to journal › Article
-
Mark
A Novel Automated Platform for Quantifying the Extent of Skeletal Tumour Involvement in Prostate Cancer Patients Using the Bone Scan Index.
(
- Contribution to journal › Article
-
Mark
Expression of Serotonin Receptors 5-HT1A, 5-HT1B, 5-HT2B and 5-HT4 in Ovary and in Ovarian Tumours.
(
- Contribution to journal › Article
- 2011
-
Mark
C-JUN INTERVENES WITH DOCETAXEL THERAPY IN CASTRATION-RESISTANT PROSTATE CANCER: AR STILL MATTERS
2011) 26th Annual Congress of the European Association of Urology In European Urology Supplements 10(2). p.294-294(
- Contribution to journal › Published meeting abstract
-
Mark
Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines.
(
- Contribution to journal › Article
-
Mark
Clinical Trial Update and Novel Therapeutic Approaches for Metastatic Prostate Cancer.
(
- Contribution to journal › Article
- 2010
-
Mark
HIF1 alpha isoforms in benign and malignant prostate tissue and their correlation to neuroendocrine differentiation
(
- Contribution to journal › Article
-
Mark
Label retaining cells and stem cell marker expression in the developing and adult mouse prostate
(
- Contribution to journal › Published meeting abstract
-
Mark
Phase II Study of the Human Anti-Epithelial Cell Adhesion Molecule Antibody Adecatumumab in Prostate Cancer Patients with Increasing Serum Levels of Prostate-Specific Antigen after Radical Prostatectomy
(
- Contribution to journal › Article
-
Mark
Burden of metastatic bone disease from genitourinary malignancies
(
- Contribution to journal › Scientific review
-
Mark
Properties and effects of a novel liquid crystal nanoparticle formulation of docetaxel in a prostate cancer mouse model.
(
- Contribution to journal › Article
-
Mark
Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature.
(
- Contribution to journal › Article
-
Mark
PCA3 as a diagnostic marker for prostate cancer: A validation study on a Swedish patient population.
(
- Contribution to journal › Article
-
Mark
Reply to Tomasz Drewa's Letter to the Editor re: Per-Anders Abrahamsson. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010;57:49-59.
(
- Contribution to journal › Letter
-
Mark
European Association of Urology. Position statement on screening for prostate cancer
(
- Contribution to journal › Debate/Note/Editorial
- 2009
-
Mark
Prostate Cancer: To Treat or Not to Treat?
(
- Contribution to journal › Article
-
Mark
Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates
(
- Contribution to journal › Scientific review
-
Mark
CYCLIN A1 MEDIATES DRUG-RESISTANT METASTATIC SPREAD OF PCA CELLS IN XENOGRAFTS IN VIVO
2009) 24th Annual Congress of the European Association of Urology In European Urology Supplements 8(4). p.343-343(
- Contribution to journal › Published meeting abstract
-
Mark
SOMATOSTATIN IS EXPRESSED IN THE HUMAN PROSTATE STEM CELL NICHE AND INHIBITS EXPANSION OF LUMINAL PRECURSOR CELLS
2009) 24th Annual Congress of the European Association of Urology In European Urology Supplements 8(4). p.248-248(
- Contribution to journal › Published meeting abstract
-
Mark
Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study
(
- Contribution to journal › Article
-
Mark
Treatment of prostate cancer with hormonal therapy in Europe
(
- Contribution to journal › Article
-
Mark
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
COMPARING TESTOSTERONE AND PSA FOR DIFFERENT BASELINE TESTOSTERONE CONCENTRATIONS DURING INITIATION OF DEGARELIX AND LEUPROLIDE TREATMENT
2009) 24th Annual Congress of the European Association of Urology In European Urology Supplements 8(4). p.130-130(
- Contribution to journal › Published meeting abstract
-
Mark
European Association of Urology Position Statement on Screening for Prostate Cancer.
(
- Contribution to journal › Letter
-
Mark
The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia.
(
- Contribution to journal › Article
-
Mark
The developing role of hormonal therapy in the treatment of prostate cancer.
(
- Contribution to journal › Article
-
Mark
EAU-a work in progress-what comes next?
(
- Contribution to journal › Letter
-
Mark
The effect of a novel botanical agent TBS-101 on invasive prostate cancer in animal models.
(
- Contribution to journal › Article
- 2008
-
Mark
Malignant lesions in the ventral prostate of alloxan-induced diabetic rats
(
- Contribution to journal › Article
-
Mark
Hormonal regulation of beta(2)-adrenergic receptor level in prostate cancer
(
- Contribution to journal › Article
-
Mark
The Identification of a Novel Stromal Stem/Progenitor Cell Phenotype in the Human Adult Prostate
2008) 23rd Annual Congress of the European Association of Urology, 2008 In European Urology Supplements 7(3). p.93-93(
- Contribution to journal › Published meeting abstract
-
Mark
Intermittent DHT administration enhances effect of docetaxel in a xenograft model by modulation of ER beta, AR and NEK2
2008) 23rd Annual Congress of the European Association of Urology, 2008 In European Urology Supplements 7(3). p.278-278(
- Contribution to journal › Published meeting abstract
-
Mark
Reduced risk of prostate cancer in infertile men compared to men with proven fertility: A nested case-control study
2008) 23rd Annual Congress of the European Association of Urology, 2008 In European Urology Supplements 7(3). p.197-197(
- Contribution to journal › Published meeting abstract
-
Mark
PSA-based screening for prostate cancer: How does it compare with other cancer screening tests?
(
- Contribution to journal › Scientific review
-
Mark
The characterization of epithelial and stromal subsets of candidate stem/progenitor cells in the human adult prostate.
(
- Contribution to journal › Article
-
Mark
Do we need PSA and early detection of prostate cancer?
(
- Contribution to journal › Article
-
Mark
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
(
- Contribution to journal › Article
-
Mark
Nordic Observational Study Evaluating Safety And Analgesic Use In Patients With Advanced Cancer Under Zoledronic Acid Treatment Interim Analysis
(
- Contribution to journal › Published meeting abstract
-
Mark
Nordic observational study evaluating safety and analgesic consumption in patients with advanced cancer under zoledronic acid (ZOMETA (R)) treatment: NOSAZ-interim analysis
2008) 23rd Annual Congress of the European Association of Urology, 2008 In European Urology Supplements 7(3). p.232-232(
- Contribution to journal › Published meeting abstract
-
Mark
Management of advanced prostate cancer: can we improve on androgen deprivation therapy?
(
- Contribution to journal › Article
-
Mark
Prostate cancer and active surveillance.
(
- Contribution to journal › Article
-
Mark
Delta-Like 1 (Dlk-1), a Novel Marker of Prostate Basal and Candidate Epithelial Stem Cells, Is Downregulated by Notch Signalling in Intermediate/Transit Amplifying Cells of the Human Prostate.
(
- Contribution to journal › Article
- 2007
-
Mark
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
(
- Contribution to journal › Article
-
Mark
Active surveillance vs radical prostatectomy.
(
- Contribution to journal › Article
-
Mark
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer
(
- Contribution to journal › Article
-
Mark
Adjuvant radiotherapy after radical prostatectomy
(
- Contribution to journal › Article
-
Mark
The continuing role of PSA in the detection and management of prostate cancer
(
- Contribution to journal › Article
- 2006
-
Mark
Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer
(
- Contribution to journal › Article
-
Mark
Hormone therapy: Improving therapy decisions and monitoring
(
- Contribution to journal › Article
-
Mark
The role of finasteride in the management of BPH and in the prevention of prostate cancer - Introduction
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Interview with Professor Per-Anders Abrahamson: Angiogenesis and renal cell carcinoma
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The Prostate Cancer Prevention Trial and its implications for clinical practice: A European consensus
(
- Contribution to journal › Article
-
Mark
The role of PSA kinetics in the management of prostate cancer
(
- Contribution to journal › Article
-
Mark
Advances in Biomarkers for Prostate Diseases
2006) p.85-85(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2005
-
Mark
Expression of Serotonin Receptors 2B and 4 in Human Prostate Cancer Tissue and Effects of Their Antagonists on Prostate Cancer Cell Lines.
(
- Contribution to journal › Article
-
Mark
The 5alpha-Reductase Type II A49T and V89L High-Activity Allelic Variants are More Common in Men with Prostate Cancer Compared with the General Population.
(
- Contribution to journal › Article
-
Mark
Neuroendocrine differentiation in prostate cancer: Implications for new treatment modalities
(
- Contribution to journal › Scientific review
-
Mark
Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer.
(
- Contribution to journal › Scientific review
-
Mark
Prognostic value of serum markers for prostate cancer
(
- Contribution to journal › Article
- 2004
-
Mark
Androgen receptor CAG repeat length correlates with semen PSA levels in adolescence.
(
- Contribution to journal › Article
-
Mark
Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines.
(
- Contribution to journal › Article
-
Mark
Long-term testosterone stimulation induces hyperplasia in the guinea-pig prostate.
(
- Contribution to journal › Article
-
Mark
Pathophysiology of bone metastases in prostate cancer
(
- Contribution to journal › Article
-
Mark
Cystatin C is highly expressed in the human male reproductive system.
(
- Contribution to journal › Article
- 2003
-
Mark
No association between mutations in the human androgen receptor GGN repeat and inter-sex conditions
(
- Contribution to journal › Article
-
Mark
Neuroendocrine differentiation in prostatic carcinoma.
(
- Contribution to journal › Article
-
Mark
Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer
(
- Contribution to journal › Scientific review
-
Mark
Revolutions in the management of hormone-refractory prostate cancer
(
- Contribution to journal › Debate/Note/Editorial
- 2002
-
Mark
Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines.
(
- Contribution to journal › Article
-
Mark
Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial
(
- Contribution to journal › Article
-
Mark
Neuroendocrine Mediators in Prostate Cancer Progression
2002) p.279-279(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer.
(
- Contribution to journal › Article
- 2001
-
Mark
Neuroendocrine cells and nerves in the prostate of the guinea pig: effects of peripheral denervation and castration
(
- Contribution to journal › Article
-
Mark
Neuroendocrine pathogenesis in adenocarcinoma of the prostate
(
- Contribution to journal › Article
- 2000
-
Mark
Calcitonin and calcitonin gene-related peptide in the human prostate gland
(
- Contribution to journal › Article
- 1999
-
Mark
Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL
(
- Contribution to journal › Article
-
Mark
Localization of protein gene product 9.5 immunoreactivity in derivatives of the human Wolffian duct and in prostate cancer
(
- Contribution to journal › Article
- 1998
-
Mark
Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum
(
- Contribution to journal › Article
-
Mark
Forskningsframsteg om hereditär prostatacancer. Riskfamiljer bör kartläggas och erbjudas screening
(
- Contribution to journal › Article
- 1997
-
Mark
Molecular forms of serum prostate-specific antigen : The clinical value of percent free prostate-specific antigen
(
- Contribution to journal › Article
- 1996
-
Mark
Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer
(
- Contribution to journal › Article
- 1995
-
Mark
Free, Complexed and Total Serum Prostate Specific Antigen : The Establishment of Appropriate Reference Ranges for their Concentrations and Ratios
(
- Contribution to journal › Article
- 1994
-
Mark
Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia
(
- Contribution to journal › Article
-
Mark
Alpha 1-Antichymotrypsin Production in PSA-Producing Cells Is Common in Prostate Cancer but Rare in Benign Prostatic Hyperplasia : REPLY BY THE AUTHORS
(
- Contribution to journal › Letter
-
Mark
Effects of radical prostatectomy and transurethral microwave thermotherapy on free, complex-bound and total prostate-specific antigen in serum
(
- Contribution to journal › Article
- 1993
-
Mark
Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium
(
- Contribution to journal › Article
- 1992
-
Mark
Protein C inhibitor in human body fluids. Seminal plasma is rich in inhibitor antigen deriving from cells throughout the male reproductive system
(
- Contribution to journal › Article
-
Mark
Prostate specific antigen predominantly forms a complex with alpha1‐antichymotrypsin in blood. Implications for procedures to measure prostate specific antigen in serum
(
- Contribution to journal › Article
- 1990
-
Mark
Species‐ and organ‐specificity of secretory proteins derived from human prostate and seminal vesicles
(
- Contribution to journal › Article
-
Mark
Three predominant prostatic proteins : Drei vorherrschende Prostataproteine
(
- Contribution to journal › Article
- 1989
-
Mark
Radioimmunoassay of beta-microseminoprotein, a prostatic-secreted protein present in sera of both men and women
(
- Contribution to journal › Article
-
Mark
Molecular cloning of a small prostate protein, known as beta-microsemenoprotein, PSP94 or beta-inhibin, and demonstration of transcripts in non-genital tissues
(
- Contribution to journal › Article
-
Mark
Semenogelin, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa
(
- Contribution to journal › Article
-
Mark
Partial characterization of a thyroid‐stimulating hormone‐like peptide in neuroendocrine cells of the human prostate gland
(
- Contribution to journal › Article
- 1988
-
Mark
Three predominant proteins secreted by the human prostate gland
(
- Contribution to journal › Article
-
Mark
Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands
(
- Contribution to journal › Article